Edition:
United Kingdom

Pacific Biosciences of California Inc (PACB.OQ)

PACB.OQ on NASDAQ Stock Exchange Global Select Market

6.06USD
9:00pm BST
Change (% chg)

$-0.17 (-2.73%)
Prev Close
$6.23
Open
$6.23
Day's High
$6.23
Day's Low
$6.05
Volume
164,131
Avg. Vol
368,556
52-wk High
$7.84
52-wk Low
$3.33

Latest Key Developments (Source: Significant Developments)

Pacific Biosciences Of California Reports Qtrly Loss Per Share $0.20
Friday, 3 May 2019 

May 3 (Reuters) - Pacific Biosciences of California Inc ::PACIFIC BIOSCIENCES OF CALIFORNIA, INC. ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.GIVEN PENDING MERGER WITH ILLUMINA, WILL NOT BE HOSTING CONFERENCE CALL TO DISCUSS ITS RESULTS FOR Q1.QTRLY LOSS PER SHARE $0.20.Q1 EARNINGS PER SHARE VIEW $-0.15 -- REFINITIV IBES DATA.QTRLY TOTAL REVENUE $16.4 MILLION VERSUS $19.4 MILLION.Q1 REVENUE VIEW $21.6 MILLION -- REFINITIV IBES DATA.PACIFIC BIOSCIENCES OF CALIFORNIA - GIVEN PENDING MERGER WITH ILLUMINA, ALSO DOES NOT EXPECT TO HOST CONF CALL TO DISCUSS ITS RESULTS FOR FUTURE QUARTERS.  Full Article

Oxford Nanopore Prevails Against PacBio In Final Decision By U.S. Court Of Appeal
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Oxford Nanopore::OXFORD NANOPORE - U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT TODAY UPHELD DECISION OF INTERNATIONAL TRADE COMMISSION (ITC) IN FAVOUR OF OXFORD NANOPORE.  Full Article

Pacific Biosciences Of California Q2 Loss Per Share $0.17
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Pacific Biosciences of California Inc ::PACIFIC BIOSCIENCES OF CALIFORNIA, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $21.6 MILLION VERSUS I/B/E/S VIEW $23.8 MILLION.QTRLY LOSS PER SHARE $0.17.PACIFIC BIOSCIENCES OF CALIFORNIA - CASH, CASH EQUIVALENTS AND INVESTMENTS, AT JUNE 30, 2018 TOTALED $63.5 MILLION, VERSUS $62.9 MILLION AT DECEMBER 31, 2017.  Full Article

Pacific Biosciences Of California reports Q3 revenue $23.5 mln
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Pacific Biosciences Of California Inc :Pacific Biosciences Of California Inc announces third quarter 2017 financial results.Q3 revenue $23.5 million versus I/B/E/S view $28.5 million.Pacific Biosciences Of California Inc - ‍net loss for q3 of 2017 was $22.0 million, compared to $17.5 million for q3 of 2016​.Pacific Biosciences Of California Inc qtrly loss per share $‍0.19​.  Full Article

Photo

UK's CMA says Illumina-Pacific Biosciences deal could hurt competition

Britain's competition watchdog said on Tuesday the planned $1.2 billion merger between gene sequencing company Illumina Inc and smaller rival Pacific Biosciences of California Inc may be a threat to competition in the country.